Colleen Silk: Fueling Innovation in Rare Bleeding Disorders at THSNA 2026
Colleen Silk, Corporate Vice President, Rare Disease at Novo Nordisk, shared on LinkedIn:
”This weekend I attended the 2026 Thrombosis and Hemostasis Summit of North America alongside many dedicated colleagues from our Rare Disease team.
I left feeling inspired by the collaboration and expertise that went into making this meeting such a valuable experience.
It was energizing to connect with the thrombosis and hemostasis community, sharing scientific perspectives and how we’re working to shape the future of care for people living with hemophilia.
From scientific presentations to educational symposia, our presence reflected a continued focus on innovation and progress for the rare bleeding disorders community.
THSNA reinforced the power of fueling conversations, sharing insights, and learning together matters as we work to accelerate progress in this area of unmet need.”
Stay updated with Hemostasis Today.
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies
-
Aug 10, 2026, 17:35Chokri Ben Lamine: Balancing Holistic Care and Precision in Hematology
-
Aug 10, 2026, 17:14Anna Stanizzi: Patient Blood Management as a New Model of Personalized Care
-
Aug 10, 2026, 17:12Odong Christopher: New Research on Ischemic Stroke Prediction in Uganda
-
Aug 10, 2026, 16:58Jeff Szer AM: Advancing the Management of Paroxysmal Nocturnal Hemoglobinuria